Novartis' investigational cancer agent imatinib trade name is changed in U.S. from "Glivec" to "Gleevec" to avoid possible confusion with Pharmacia's diabetes drug Glyset, Novartis says. The name "Glivec" will continue to be used in all other countries where applications have been submitted. The Gleevec NDA was filed Feb. 27 for second-line treatment of chronic myeloid leukemia and is receiving a priority review
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
